Exhibit 10.01
 First Amended and Restated
 ARA Alliance, Purchase and Production Agreement
 By and Between
 Martek Biosciences Corporation
 And
 DSM Food Specialties B.V.
 Dated as of July 13, 2009
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



TABLE OF CONTENTS
 1. INTRODUCTION
    
    
    12. DEFINITIONS
    
    
    23. SUPPLY, PRODUCTION AND ORDERS
    
    
    153.1. Martek Requirements for ARA Products
    
    
    153.2. DSM Production
    
    
    163.3. Martek Production
    
    
    173.4. Extraction and RBD Services
    
    
    203.5. Martek Three Year Rolling Forecasts; Martek Firm Orders
    
    
    233.6. DSM Three Year Rolling Forecast; DSM Firm Orders
    
    
    243.7. Delivery Instructions
    
    
    243.8. Shipment
    
    
    253.9. Order Fulfillment
    
    
    263.10. Limitation on Breach
    
    
    264. QUALITY AND VERIFICATION
    
    
    274.1. Verification of Production
    
    
    274.2. Certification of Analysis
    
    
    274.3. Refined Biomass Specification; Specification Changes
    
    
    294.4. Ongoing Biomass Quality Review; Verification of Production Changes
    
    
    304.5. Inspection
    
    
    304.6. Manufacturing Changes
    
    
    314.7. ARA Product Non-Conformity Procedure; Rework and Destruction
    
    
    344.8. Compliance
    
    
    35
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



4.9. Disclaimers
    
    
    365. MARKETING
    
    
    375.1. Expansion of Fields of Use
    
    
    375.2. Customer Contracts
    
    
    375.3. Priority of ARA Marketing
    
    
    385.4. * Arrangements with * Customers
    
    
    385.5. Notification and Challenge Procedure
    
    
    396. FINANCIAL MATTERS
    
    
    426.1. Amounts Payable by Martek
    
    
    426.2. Reconciliations to the Budgeted Price
    
    
    466.3. Adjustments to the Budgeted Price
    
    
    486.4. Amounts Payable by DSM
    
    
    506.5. Invoices and Payment
    
    
    516.6. Interest Charges for Inventory
    
    
    526.7. Margin Protection
    
    
    526.8. Stop Loss
    
    
    536.9. Review of Alliance Structure and Economics; Renegotiation of Pricing Arrangements
    
    
    546.10. Transparency
    
    
    546.11. Books and Records
    
    
    556.12. Break Up Fee
    
    
    566.13. Considerations for Payments and Volume Commitments
    
    
    567. PRODUCT DEVELOPMENTS AND PATENTS
    
    
    577.1. R&D Collaboration
    
    
    57
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



7.2. Intellectual Property Rights
    
    
    597.3. Prosecution, Maintenance and Enforcement
    
    
    627.4. Intellectual Property Licenses
    
    
    667.5. Technology Transfers
    
    
    727.6. Protection of Other Joint Intellectual Property
    
    
    738. ORGANIZATION (COMMUNICATION, COMMITTEES)
    
    
    748.1. Formation of the Committee
    
    
    748.2. Meetings of the Committee
    
    
    748.3. Status Reports of the Committee
    
    
    748.4. Scope of the Committee Meetings
    
    
    758.5. Deadlock Within a Committee
    
    
    758.6. Deadlock Within the Committee Over Factual Matters
    
    
    758.7. Deadlock Within the Committee Over Non-Factual Matters
    
    
    768.8. External Communication
    
    
    769. TERM; TERMINATION; DAMAGES
    
    
    779.1. Term
    
    
    779.2. Termination for Cause
    
    
    779.3. Effect of Expiration and Termination on Intellectual Property Rights
    
    
    809.4. Other Effects of Termination; Damages; Cap
    
    
    849.5. Limitation of Liability
    
    
    8810. GENERAL
    
    
    8810.1. Non-Solicitation
    
    
    8810.2. Confidential Information
    
    
    8910.3. Survival
    
    
    89
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



10.4. Trademarks
    
    
    9010.5. Disputes; Arbitration
    
    
    9110.6. Regulatory Matters
    
    
    9210.7. Assignment, Delegation and Subrogation; Insurance Inspection
    
    
    9210.8. Amendments and Waivers
    
    
    9310.9. Severability
    
    
    9310.10. Relationship of the Parties
    
    
    9410.11. Notices
    
    
    9410.12. Governing Law
    
    
    9510.13. Force Majeure
    
    
    9510.14. No Waivers
    
    
    9510.15. Entire Agreement
    
    
    9610.16. Counterparts
    
    
    9610.17. Guarantees
    
    
    9610.18. Hierarchy of Documents
    
    
    96
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



MARTEK BIOSCIENCES CORPORATION
DSM FOOD SPECIALTIES BV
 FIRST AMENDED AND RESTATED
 ARA ALLIANCE, PURCHASE AND PRODUCTION AGREEMENT
 DSM Food Specialties B.V. Besloten Vennootschap MARTEK BIOSCIENCES CORPORATION
 1. INTRODUCTION
 1.1
 1.2
 1.3 ,
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  1




---



##### 



1.4
 1.5
 1.6
 1.7
 1.8
  2. DEFINITIONS
 2.1.
 2.2.
 2.3.
 2.4.
 2.5.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  2




---



##### 



2.6.
 2.7.
 2.8.
 2.9.
 2.10.
 2.11.
 2.12.
 2.13.
 2.14.
 2.15.
 2.16.
 2.17.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  3




---



##### 



2.18.
 2.19.
 2.20.
 2.21.
 2.22.
 2.23.
 2.24.
 2.25.
 2.26.
 2.27.
 2.28.
 2.29.
 2.30.
 2.31.
 2.32.
 2.33.
 2.34.
 2.35.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  4




---



##### 



2.36.
 2.37.
 2.38.
 2.39.
 2.40.
 2.41.
 2.42.
 2.43.
 2.44.
 2.45.
 2.46.
 2.47.
 2.48.
 2.49.
 2.50.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  5




---



##### 



2.51.
 2.52.
 2.53.
 2.54.
 2.55.
 2.56.
 2.57.
 2.58.
 2.59.
 2.60.
 2.61.
 2.62.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  6




---



##### 



2.63.
 2.64.
 2.65.
 2.66.
 2.67.
 2.68.
 2.69.
 2.70.
 2.71.
 2.72.
 2.73.
 2.74.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  7




---



##### 



2.75.
 2.76.
 2.77.
 2.78.
 2.79.
 2.80.
 2.81.
 2.82.
 2.83.
 2.84.
 2.85.
 2.86.
 2.87.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  8




---



##### 



2.88.
 2.89.
 2.90.
 2.91.
 2.92.
 2.93.
 2.94.
 2.95.
 2.96.
 2.97.
 2.98.
 2.99.
 2.100.
 2.101.
 2.102.
 2.103.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  9




---



##### 



2.104.
 2.105.
 2.106.
 2.107.
 2.108.
 2.109.
 2.110.
 2.111.
 2.112.
 2.113.
 2.114.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  10




---



##### 



2.115.
 2.116.
 2.117.
 2.118.
 2.119.
 2.120.
 2.121.
 2.122.
 2.123.
 2.124.
 2.125.
 2.126.
 2.127.
 2.128.
 2.129.
 2.130.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  11




---



##### 



2.131.
 2.132.
 2.133.
 2.134.
 2.135.
 2.136.
 2.137.
 2.138.
 2.139.
 2.140.
 2.141.
 2.142.
 2.143.
 2.144.
 2.145.
 2.146.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  12




---



##### 



2.147.
 2.148.
 2.149.
 2.150.
 2.151.
 2.152.
 2.153.
 2.154.
 2.155.
 2.156.
 2.157.
 2.158.
 2.159.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  13




---



##### 



2.160.
 2.161.
 2.162.
 2.163.
 2.164.
 2.165.
 2.166.
 2.167.
 2.168.
 2.169.
 2.170.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  14




---



##### 



3. SUPPLY, PRODUCTION AND ORDERS
 3.1. Martek Requirements for ARA Products .
     *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  15




---



##### 



3.2. DSM Production.
      *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  16




---



##### 



3.3. Martek Production .
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  17




---



##### 



st st
 ,
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  18




---



##### 



then
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  19




---



##### 



3.4. Extraction and RBD Services.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  20




---



##### 



st st
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  21




---



##### 



mutatis mutandis
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  22




---



##### 



3.5. Martek Three Year Rolling Forecasts; Martek Firm Orders.
       *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  23




---



##### 



3.6. DSM Three Year Rolling Forecast; DSM Firm Orders.
      3.7. Delivery Instructions.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  24




---



##### 



3.8. Shipment .
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  25




---



##### 



3.9. Order Fulfillment .
   3.10. Limitation on Breach .
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  26




---



##### 



4. QUALITY AND VERIFICATION
 4.1. Verification of Production.
  4.2. Certification of Analysis .
     *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  27




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  28




---



##### 



4.3. Refined Biomass Specification; Specification Changes .
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  29




---



##### 



4.4. Ongoing Biomass Quality Review; Verification of Production Changes.
 7.1(c),
  4.5. Inspection.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  30




---



##### 



4.6. Manufacturing Changes.
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  31




---



##### 



(
 X
  =
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  32




---



##### 



.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  33




---



##### 



4.7. ARA Product Non-Conformity Procedure; Rework and Destruction.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  34




---



##### 



4.8. Compliance.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  35




---



##### 



4.9. Disclaimers.
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  36




---



##### 



5. MARKETING
 5.1. Expansion of Fields of Use.
     5.2. Customer Contracts.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  37




---



##### 



5.3. Priority of ARA Marketing.
   Units of ARA per AnnumMonthly Production Capacity
    
    New ARA Product/Field of Use* Units of ARA
    
    * Units of ARA* Units of ARA
    
    * Units of ARA* Units of ARA
    
    * Units of ARA
  5.4. * Arrangements with * Customers.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  38




---



##### 



5.5. Notification and Challenge Procedure.
 provided however
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  39




---



##### 



or
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  40




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  41




---



##### 



6. FINANCIAL MATTERS
 6.1. Amounts Payable by Martek.
     
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  42




---



##### 



(i)
    
    2009: For calendar year 2009, Martek may purchase up to * Units of ARA
at the Budgeted Price, but shall order at least * Units of ARA for delivery in 2009.
The Budgeted Price for 2009 shall be calculated based upon the following:
 
    
    The 2009 Agreed Annual Fixed Cost shall be * US Dollars ($*) resulting in a
DSM Fixed Cost per Unit of ARA equal to $* for the first * Units of ARA and $*
for any additional Units of ARA.
 
    
    The 2009 DSM Mark Up per Unit of ARA shall be equal to $* for the first *
Units of ARA and $* for any additional Units of ARA.
 
    
    The 2009 DSM Variable Cost per Unit of ARA shall be equal to $* for all
Units of ARA, determined as set forth on Schedule 6.1-B.
 (ii)
    
    2010: For calendar year 2010, Martek may purchase up to * Units of ARA
at the Budgeted Price, but shall order at least * Units of ARA for delivery in 2010.
The Budgeted Price for 2010 shall be calculated based upon the following:
 
    
    The 2010 Agreed Annual Fixed Cost shall be * US Dollars ($*) resulting in a
DSM Fixed Cost per Unit of ARA equal to $* for the first * Units of ARA and $*
for any additional Units of ARA.
 
    
    The 2010 DSM Mark Up per Unit of ARA shall be equal to $* for all Units of
ARA forecasted for 2010 pursuant to the Martek Three Year Rolling Forecast as
of November 1, 2009 and $* for any additional Units of ARA.
 
    
    The 2010 DSM Variable Cost per Unit of ARA shall be the sum of the Usages
for electricity, natural gas, yeast extract and dextrose set forth in Schedule
6.1-A multiplied by their corresponding Budgeted Rates for 2010 (except that
the rate for Other Materials shall be as set forth on Schedule 6.1-B).
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  43




---



##### 



(iii)
    
    2011: For calendar year 2011, Martek may purchase up to * Units of
ARA at the Budgeted Price, but shall order at least * Units of ARA for delivery in
2011. The Budgeted Price for 2011 shall be calculated based upon the following:
 
    
    The 2011 Agreed Annual Fixed Cost shall be * US Dollars ($*) resulting in a
DSM Fixed Cost per Unit of ARA equal to $* for the first * Units of ARA and $*
for any additional Units of ARA.
 
    
    The 2011 DSM Mark Up per Unit of ARA shall be equal to $ * for all Units of
ARA forecasted for 2011 pursuant to the Martek Three Year Rolling Forecast as
of November 1, 2010 and $* for any additional Units of ARA.
 
    
    The 2011 DSM Variable Cost per Unit of ARA shall be the sum of the Usages
for electricity, natural gas, yeast extract and dextrose set forth in Schedule
6.1-A multiplied by their corresponding Budgeted Rates for 2011 (except that
the rate for Other Materials shall be as set forth on Schedule 6.1-B).
 (iv)
    
    2012: For calendar year 2012, Martek may purchase up to * Units of ARA
at the Budgeted Price for delivery in 2012, which shall be calculated based upon the
following:
 
    
    The 2012 DSM Fixed Cost per Unit of ARA shall be the 2012 Agreed Annual
Fixed Cost of * US Dollars ($*) divided by the number of Units of ARA
forecasted for purchase by Martek for 2012 pursuant to the Martek Three Year
Rolling Forecast as of November 1, 2011, subject to a reconciliation based on
actual 2012 purchases as provided below.
 
    
    The 2012 DSM Mark Up per Unit of ARA shall be equal to $* for all Units of
ARA forecasted for 2012 pursuant to the Martek Three Year Rolling Forecast as
of November 1, 2011 and $* for any additional Units of ARA.
 
    
    The 2012 DSM Variable Cost per Unit of ARA shall be the sum of the Usages
for electricity, natural gas, yeast extract and dextrose set forth in Schedule
6.1-A multiplied by their corresponding Budgeted Rates for 2012 (except that
the rate for Other Materials shall be as set forth on Schedule 6.1-B).
 (v)
    
    2013: For calendar year 2013, Martek may purchase up to * Units of ARA
at the Budgeted Price for delivery in 2013, which shall be calculated based upon the
following:
 
    
    The 2013 DSM Fixed Cost per Unit of ARA shall be the 2013 Agreed Annual
Fixed Cost of * US Dollars ($*) divided by the number of Units of ARA
forecasted for purchase by Martek for 2013 pursuant to the Martek Three Year
Rolling Forecast as of November 1, 2012, subject to a reconciliation based on
actual 2013 purchases as provided below.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  44




---



##### 




    
    The 2013 DSM Mark Up per Unit of ARA shall be equal to $ * for all Units of
ARA forecasted for 2013 pursuant to the Martek Three Year Rolling Forecast as
of November 1, 2012 and $* for any additional Units of ARA.
 
    
    The 2013 DSM Variable Cost per Unit of ARA shall be the sum of the Usages
for electricity, natural gas, yeast extract and dextrose set forth in Schedule
6.1-A multiplied by their corresponding Budgeted Rates for 2013 (except that
the rate for Other Materials shall be as set forth on Schedule 6.1-B).
 (vi)
    
    2014: For calendar year 2014, Martek may purchase up to * Units of ARA
at the Budgeted Price for delivery in 2014, which shall be calculated based upon the
following:
 
    
    The 2014 DSM Fixed Cost per Unit of ARA shall be the 2014 Agreed Annual
Fixed Cost of * US Dollars ($*) divided by the number of Units of ARA
forecasted for purchase by Martek for 2014 pursuant to the Martek Three Year
Rolling Forecast as of November 1, 2013, subject to a reconciliation based on
actual 2014 purchases as provided below.
 
    
    The 2014 DSM Mark Up per Unit of ARA shall be equal to US$ * for all Units
of ARA forecasted for 2014 pursuant to the Martek Three Year Rolling Forecast
as of November 1, 2013 and $* for any additional Units of ARA.
 
    
    The 2014 DSM Variable Cost per Unit of ARA shall be the sum of the Usages
for electricity, natural gas, yeast extract and dextrose set forth in Schedule
6.1-A multiplied by their corresponding Budgeted Rates for 2014 (except that
the rate for Other Materials shall be as set forth on Schedule 6.1-B).
 Other Applications.
     *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  45




---



##### 



6.2. Reconciliations to the Budgeted Price.
  provided
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  46




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  47




---



##### 



6.3. Adjustments to the Budgeted Price.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  48




---



##### 



provided
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  49




---



##### 



6.4. Amounts Payable by DSM.
  provided
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  50




---



##### 



provided
 6.5. Invoices and Payment.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  51




---



##### 



6.6. Interest Charges for Inventory.
  6.7. Margin Protection.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  52




---



##### 



6.8. Stop Loss.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  53




---



##### 



6.9. Review of Alliance Structure and Economics; Renegotiation of Pricing Arrangements.
  6.10. Transparency.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  54




---



##### 



6.11. Books and Records.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  55




---



##### 



6.12. Break Up Fee.
    6.13. Considerations for Payments and Volume Commitments.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  56




---



##### 




 
 
  7. PRODUCT DEVELOPMENTS AND PATENTS
 7.1. R&D Collaboration.
 The R&D Collaboration Goals .
 The R&D Committee.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  57




---



##### 



Research Project Proposals.
  .
 R&D Costs.
 Outsourced R&D Activities.
 R&D Intellectual Property Rights from R&D Plans.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  58




---



##### 



R&D Intellectual Property Rights from Solely Funded ARA Research Projects.
 7.2. Intellectual Property Rights.
 Validity of Certain Patents of the Parties.
  ,
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  59




---



##### 



R&D Intellectual Property Rights.
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  60




---



##### 



and
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  61




---



##### 



7.3. Prosecution, Maintenance and Enforcement.
 Prosecution and Maintenance of New R&D Patents.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  62




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  63




---



##### 



Independent Enforcement.
 Enforcement.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  64




---



##### 



Proceeds of Infringement Actions.
 Proceeds from Infringement Actions *.
  Proceeds from Infringement Actions *.
   Defensive Patent Actions.
 Prosecution and Maintenance of Patents arising from Solely Funded ARA Research Projects.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  65




---



##### 



7.4. Intellectual Property Licenses.
 License of Martek Proprietary Technology.
 License of DSM Proprietary Technology.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  66




---



##### 



Toll Manufacturers and Affiliates; Sublicenses; Other Rights of Marteks Customers.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  67




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  68




---



##### 



Improvements.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  69




---



##### 



DHA License.
   Additional DSM License.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  70




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  71




---



##### 



7.5. Technology Transfers.
 Technology Transfer to DSM
 Technology Transfer to Martek
 Audit Rights.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  72




---



##### 



7.6. Protection of Other Joint Intellectual Property.
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission  73




---



##### 



8. ORGANIZATION (COMMUNICATION, COMMITTEES)
 8.1. Formation of the Committee.
   8.2. Meetings of the Committee.
  8.3. Status Reports of the Committee.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  74




---



##### 



8.4. Scope of the Committee Meetings.
   8.5. Deadlock Within a Committee.
  8.6. Deadlock Within the Committee Over Factual Matters.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  75




---



##### 



8.7. Deadlock Within the Committee Over Non-Factual Matters.
  8.8. External Communication.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  76




---



##### 



9. TERM; TERMINATION; DAMAGES
 9.1. Term.
  9.2. Termination for Cause.
     *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  77




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  78




---



##### 



then
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  79




---



##### 



9.3. Effect of Expiration and Termination on Intellectual Property Rights.
 Expiration . .
  provided, however
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  80




---



##### 



provided
  For Cause.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  81




---



##### 



Triggering Party:
  provided
 Non-Triggering Party provided
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  82




---



##### 



provided
    Effect on Research Projects
 Certain Intellectual Property Rights
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  83




---



##### 



9.4. Other Effects of Termination; Damages; Cap.
       *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  84




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  85




---



##### 



(i)
    
    One hundred fifty million dollars ($150,000,000);
  (ii)
    
    The total aggregate amount of Losses that have been theretofore awarded against
the Liable Party pursuant to an arbitration procedure conducted in accordance with
Section 10.5 of this Restated Agreement plus the amount of Losses that have
been theretofore actually paid by the Liable Party to the other party in respect of
claims of breach or failure to perform by the Liable Party that are settled between the
parties without the issuance of an arbitration award.
    *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  86




---



##### 



*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  87




---



##### 



9.5. Limitation of Liability.
   10. GENERAL
 10.1. Non-Solicitation.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  88




---



##### 



10.2. Confidential Information.
  10.3. Survival.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  89




---



##### 



10.4. Trademarks.
 Use of Martek Trademarks
 Ownership of Martek Trademarks
 DSM Trademarks mutatis
mutandis
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  90




---



##### 



10.5. Disputes; Arbitration.
 Disputes Generally
 Language; Transcript
 Decision of Arbitrators
 Expense of Arbitration
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  91




---



##### 



Provisional Remedies Not Denied
 Federal Arbitration Act.
 10.6. Regulatory Matters.
  10.7. Assignment, Delegation and Subrogation; Insurance Inspection.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  92




---



##### 



10.8. Amendments and Waivers.
  10.9. Severability.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  93




---



##### 



10.10. Relationship of the Parties.
  10.11. Notices.
  If to DSM:
    
    DSM Food Specialties B.V.A. Fleminglaan 12613 AX DelftThe NetherlandsAttention: Business Director ARAPhone: ** 31 15 279 2173Fax: ** 31 15 279 4320With a copy to:
    
    DSM Food Specialties B.V.A. Fleminglaan 12613 AX DelftThe NetherlandsAttention: Legal CounselPhone: ** 31 15 279 2557Fax: ** 15 279 4170If to Martek:
    
    Martek Biosciences Corporation6480 Dobbin RoadColumbia, Maryland 21045Attention: CEOPhone: 410-740-0081Fax: 410-740-2985With a copy to:
    
    Martek Biosciences Corporation6480 Dobbin RoadColumbia, Maryland 21045Attention: General CounselPhone: 410-740-0081Fax: 410-740-2985
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  94




---



##### 



10.12. Governing Law.
  10.13. Force Majeure.
  10.14. No Waivers.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  95




---



##### 



10.15. Entire Agreement.
  10.16. Counterparts.
  10.17. Guarantees.
    10.18. Hierarchy of Documents.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  96




---



##### 



IN WITNESS WHEREOF
 MARTEK BIOSCIENCES CORPORATION
    
    DSM FOOD SPECIALTIES B.V.By:
    
    /s/ Steve Dubin
    
    By:
    
    /s/ A.R. WesselsSteve Dubin
    
    
    
    A.R. WesselsTitle: Chief Executive Officer
    
    
    
    Title: Managing DirectorBy:
    
    /s/ Villaume KalVillaume Kal as Attorney-in-Fact forGeert Jan Nieboer, Managing
DirectorTitle: Business Director ARA
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the
Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission  97




---



##### 



SCHEDULES
 TO THE
 FIRST AMENDED AND RESTATED
 ARA ALLIANCE, PURCHASE AND PRODUCTION AGREEMENT
 BY AND BETWEEN
 MARTEK BIOSCIENCES CORPORATION
 AND
 DSM FOOD SPECIALTIES B.V.
 Dated as of July 13, 2009
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



LIST OF SCHEDULES
 Schedule 2.12
    
    ARA Assay ProceduresSchedule 2.16
    
    DSM Biomass SpecificationsSchedule 2.28
    
    DSM Crude Oil SpecificationsSchedule 2.47
    
    DSM CostsSchedule 2.54
    
    DSM PatentsSchedule 2.55
    
    DSM Know-howSchedule 2.64
    
    Excluded Subject MatterSchedule 2.69
    
    Martek Finished Oil SpecificationsSchedule 2.77
    
    Guaranty AgreementSchedule 2.104
    
    Martek CostsSchedule 2.108
    
    Martek PatentsSchedule 2.109
    
    Martek Know-howSchedule 2.118
    
    * CustomersSchedule 4.2(a)
    
    DSM ARA Biomass Certificate of AnalysisSchedule 4.2(b)
    
    Martek Finished Oil Certificate of AnalysisSchedule 4.6(a)
    
    Manufacturing ChangesSchedule 4.6(b)
    
    Qualification RequirementsSchedule 6.1-A
    
    Belvidere UsagesSchedule 6.1-B
    
    2009 DSM Variable Costs per Unit of ARASchedule 6.2-A
    
    2009 Quarterly Reconciliation FormatSchedule 6.2-B
    
    2010-2014 Quarterly Reconciliation FormatSchedule 6.3(a)
    
    DSM Fixed Cost Payment Calculation in the Event of DSM ShortfallsSchedule 9.4(d)-1
    
    Annual Depreciation of Undepreciated * CostsSchedule 9.4(d)-2
    
    Annual Depreciation of Undepreciated Pre-2004 Costs
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.12
ARA ASSAY PROCEDURES
 Determination of the Units of ARA in Biomass:
 *
 Determination of the Units of ARA in Crude Oil and Finished Oil:
 *
 
    
    HEL *
 
    
    ARA in HEL, Crude Oil, and Finished Oil is determined by * or equivalent method. This
method has been subject to round robin testing and is currently controlled by
inter-laboratory comparison. Data used for the determination of Units of ARA shall only be
generated by a laboratory that has either taken part in these tests or has been validated
to comply with the variability defined in the round robin test as acceptable.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.16
DSM BIOMASS SPECIFICATIONS
 (DSM LOGO)
    
    PRODUCT SPECIFICATION FORM
    
    ARA-PSF-004MARA Biomass
    
    Revision 5Product 2984
    
    July 13, 2009
 Parameter
    
    Specification Limits
    
    Test MethodRelease Specifications (a)Description
    
    Extruded m. alpina biomass pellets
    
    VisualBiomass Color
    
    Brown
    
    VisualSmell
    
    Characteristic
    
    Olfactory*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *Control Specifications (b)Lab Extracted Crude Oil Color
    
    Light to Medium Yellow
    
    Visual*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
   
    
    Below -2° C +/- 3°C, preferably lower temperatures
 
    
    Protected from light
 
    
    Dry conditions
  
    
    Big Bags (polypropylene with polyethylene liner), anti static
 
    
    Labeled with product number, batch number, production number,
production date and storage conditions on both inner and outer bag
 
    
    *
  (a)
    
    Release Specifications  unconditional release of biomass
 (b)
    
    Control specifications  tested every * and for each experimental batch to monitor
product quality and process consistency; Martek will be directly notified when out of
specification
 (c)
    
    * ARA average in extracted crude oil over *of production(d)
    
    Measured in HEL *(e)
    
    Equivalent methods may be used if mutually agreed upon by DSM and Martek in advance
 (f)
    
    The upper ARA potency limit will be increased in steps of *when * of the same
fermentation protocol within each step (i.e., *) meet all finished ARASCO oil analytical,
stability and sensory specifications
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.28
DSM CRUDE OIL SPECIFICATIONS
 (DSM LOGO)
    
    PRODUCT SPECIFICATION FORM
    
    ARA-PSF-001MARA Crude Oil
    
    Revision 522 June 2005
 Product no: 2983
 Parameters
    
    Approval limit (*)
    
    Discussion Range (*)
    
    MethodsRelease specificationsAppearance
    
    Typical at 25°C
    
    
    
    VisualColor
    
    Light-medium yellow
    
    
    
    VisualSmell
    
    Typical  free of any rancid odor
    
    
    
    olfactory*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    
    
    **
    
    *
    
    *
    
    **
    
    *
    
    
    
    *
 Parameters
    
    Specification Limit (*)
    
    MethodsControl specifications (c)*
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *Control specifications (*);
**
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
 In-process control parameters (*):
 Parameters
    
    Control limit (d)
    
    Methods*
    
    *
    
    *
 Scope
    
    Omichem & NaturexKosher
    
    YesHALAL
    
    NoNon-GMO
    
    Yes
 (a)
    
    Release Specifications  Unconditional release of material(b)
    
    Results within these limits shall be discussed with Martek prior to approval(c)
    
    Control specifications  To monitor the quality of the product and the consistency of the
process; Martek will be directly notified when out of specification(d)
    
    In-process control parameters  Corrective actions will be taken when the control limits are
exceeded. No impact on product release(e)
    
    *(average per shipment of oil)*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 




    
    below -18°C
    
    Protected from light
    
    Dry conditions
  
    
    Under Nitrogen
    
    200 kg food grade phenolic coated lined drums (tight head) with DSM label*
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.47
DSM COSTS
 Included Costs:
  st st
  Excluded Costs:
  
    
    All costs related to the importing and re-exporting of ARA products sent to Martek that
do not meet Martek Specifications, including but not limited to related freight, tariffs
and warehousing costs.
 
    
    Costs related to reworking material that originally did not meet Martek Specifications
pursuant to Section 4.7 of the Agreement.
 
    
    Legal costs associated with negotiating and drafting the Alliance Agreement as amended
and the Restated Agreement.
 
    
    Production Startup Costs.
 
    
    R&D Contribution pursuant to Section 7.1(d).
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.54
DSM PATENTS
 Patent #
    
    Title
    
    SummaryWO 97/36996
    
    Process for the preparation of
a granular microbial biomass
and isolation of valuable
compounds therefrom
    
    A process for the
isolation of desired
compound(s) from a
microbial biomass is
disclosed, wherein the
microbial biomass
(which, if necessary,
is pre-treated to give
a dry matter content
of from 25 to 80% is
granulated (e.g. by
extrusion) and then
dried to a dry matter
content of at least
80%. The granulation
of the biomass to
granules significantly
eases subsequent
drying of the biomass
(which can be stored
as dried granules) and
gives higher yields on
extraction of the
compound(s).WO 97/37032
    
    Fatty acid containing
Oil from pasteurized biomass
    
    In one aspect the
present invention
provides a process for
the isolation of one
or more compound(s)
from a microbial
biomass, the process
comprising:a)    culturing
microorganisms in a
fermentation broth
under conditions
whereby the
microorganisms produce
the compoundb)    pasteurizing either
the fermentation broth
or a microbial biomass
derived therefrom; andc)    extracting,
isolating or
recovering the
compound from the
microbial biomassWO 97/35487
    
    Solid water soluble
PUFA-carrying particles
    
    The present invention
relates to a process
for the preparation of
a polyunsaturated
fatty acid
(PUFA)-containing
composition where a
PUFA-containing lipid
is adsorbed onto a
solid carrier such as
a powder. This can be
used in a process for
preparing an infant
formula, such as where
the powdered
PUFA-containing lipid
is added after an
emulsion of oil and
water phases has been
formed.WO 97/35488
    
    Late addition of PUFAs in
production of infant formula
    
    The present invention
relates to a process
for the preparation of
a polyunsaturated
fatty acid
(PUFA)-containing
food, such as an
infant formula, where
a composition
comprising a PUFA is
added at a late stage
of the infant formula
preparation process in
this way, the PUFAs is
minimally exposed to
conditions during the
process that induce
degradation of the
PUFAs.WO 97/43362
    
    Sterol extraction with polar
solvent
    
    The present invention
relates to a process
of treating an oil,
the process comprising
contacting the oil
with a polar solvent,
and then separating
the solvent containing
the compound from the
so treated oil. The
oil is microbially
derived, and extracted
either form a
fermentation broth or
a filtrate thereof
using hexane. The
compound to be
extracted is usually a
sterol or a
diglyceride. The
solvent is ethanol
having up to 5% of
water. The oil an
contain a
plyunsaturated fatty
acid such as C28, C20
or C22 w-e, or w-6
fatty acid, such as
arachidonic acid.WO 99/65327
    
    Microbial ARA for use in
marine feed
    
    A marine feed
composition is
described comprising
microbially derived
arachidonic acid (ARA)
or ARA in the form of
a triglyceride. The
ARA is suitably
produced by a fungus,
such as of the genus
Mortierella, although
the feed composition
itself is free of
microbial cells. These
forms of ARA have been
found to give better
growth and
pigmentation promotion
in marine organisms
(shrimps and fish)
than corresponding
phospholipid forms of
ARA from fish oil. The
ARA can be in the form
of an oil, e.g. an
oil-in-water emulsion
or may first be fed to
larvae, rotifers or
nauplii which are
themselves included in
a composition as
live feed for larger
organisms.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Patent #
    
    Title
    
    SummaryWO 00/21524
    
    PUFA supplement /ARA for
pregnant women
    
    Edible formulations,
such as
polyunsaturated fatty
acids (PUFAs) such as
pharmaceutical
compositions or
nutritional
supplements, are
disclosed comprising
arachidonic acid
(ARA). They are
adapted to deliver
from 150 mg to 1 g per
day of ARA and may
contain other PUFAs,
for example
docosahexaenoic acid
(DHA) at a ration of
ARA: DHA of 1:1 to 1:2
are also disclosed, as
are foodstuffs
comprising of 0.1 to
5% of ARA. Such
formulations can be
used to increase ARA
levels in vivo, for
example in pregnant
women or for people
who have diseases or
conditions associated
with low ARA levels.WO 02/10423
    
    Isolation of microbial oils
    
    The extraction of a
microbial or single
cell oil, for example
comprising one or more
polyunsaturated fatty
acids (PUFAs),
directly form
microbial cells is
disclosed which avoids
the need for solvents.WO 02/10322
    
    Purifying crude PUFA oils
    
    A process for
preparing an oil
mixture of an w-6 PUFA
(such as ARA) with w-3
PUFA (such as DHA
and/or EPA is
described which can be
included into edible
formulations such as
foodstuffs, and in
particular infant
formulas.WO 04/001021
    
    Pasteurization of biomass
    
    An improved
pasteurization
protocol for
pasteurizing microbial
cells is disclosed.
The protocol has three
stages, a first
heating stage, a
second plateau stage
at which the cells are
held at a (maximum
and) constant
temperature, and a
third cooling stage.WO 04/009827
    
    Preparation of microbial oil
    
    The present invention
provides a process for
the production of a
microbial oil,
comprising culturing a
micro-organism in a
two-stage process
where, in a last stage
that precedes the end
of fermentation, the
carbon source is: consumed by the
micro-organisms at a
rate greater than it
is added to the
medium; added at a
rate < 0.30 M
carbon/kg medium; or
is rate limiting on
the growth of the
micro-organism. The
Micro-organism thus
have the carbon source
restricted so that
they preferentially
metobolise fats or
lipids other than
arachidonic acid
(ARA), so increasing
th proportion of ARA
in the cells. A
microbial oil is then
recovered from the
micro-organism, using
hexane as a solvent,
that has at least 50 %
ARA and at least 90 %
triglycerides.WO 98/37179A2
    
    Fermentative production of
valuable compounds on an
industrial scale using
chemically defined media
    
    A process for the
production of a
valuable compound,
comprising the steps
of: fermentation of a
microbial strain on an
industrial scale in a
fermentation medium
which is a chemically
defined medium
essentially composed
of chemically defined
constituents, and
recovery of the
valuable compound from
the fermentation
broth.
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.55
DSM KNOW-HOW
 Status :
 Main process characteristics:
 
 
 Main fields of expertise:
 Strains:
 
    
    A number of ARA producing strains of different organisms
 
    
    Main line of producers: Mortierella alpina
 Fermentation technology:
 
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *
 Pasteurization technology:
 
    
    *
 
    
    *
 
    
    *
 Downstream processing:
 
    
    *
 
    
    *
 
    
    *
 Extraction of biomass:
 
    
    *
    
    *
 Process developments developed, not implemented:
 
    
    *
 
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Toxicology, safety studies:
 
    
    *
 
    
    *
 
    
    *
 Nutrition:
 
    
    *
 
    
    *
 Application areas:
 
    
    *
 New fields of investigation:
 Increase fermentation efficiency:
 
    
    *
 
    
    *
 
    
    *
 
    
    *
 Downstream processing:
 
    
    *
 
    
    *
 
    
    *
 Extraction:
 
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.64
EXCLUDED SUBJECT MATTER
 SR No./ Huntion
    
    
    
    Application or
    
    Appl. Date orNo./ Rothwell No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000106
    
    AU
    
    661297
    
    7-Nov-1995
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000109
    
    BR
    
    PI920526-5
    
    22-Jan-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Appealed62611.000110
    
    CA
    
    2101274
    
    15-Dec-1998
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000358
    
    EP
    
    07075341.3
    
    22-Jan-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Published62611.000354
    
    EP
    
    07002670.3
    
    22-Jan-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Published62611.000387
    
    EP
    
    8005794.6
    
    22-Jan-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Published62611.000380
    
    HK
    
    08102811.5
    
    11-Mar-2008
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Published62611.000118
    
    ID
    
    ID0000174
    
    20-Jun-1995
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000120
    
    IL
    
    114253
    
    14-Oct-1997
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000119
    
    IL
    
    100733
    
    1-Apr-1996
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000133
    
    KR
    
    321543
    
    9-Jan-2002
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000135
    
    KR
    
    313987
    
    25-Oct-2001
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000137
    
    LK
    
    10526
    
    17-Jun-1994
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000127
    
    NZ
    
    241359
    
    16-Feb-1995
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000129
    
    PH
    
    1992-43812
    
    23-Nov-2001
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000130
    
    RU
    
    2093996
    
    27-Oct-1997
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000131
    
    SG
    
    49307
    
    10-Jan-2002
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000141
    
    US
    
    5374657
    
    20-Dec-1994
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000142
    
    US
    
    5550156
    
    27-Aug-1996
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted62611.000128
    
    WO
    
    PCT/US92/00522
    
    22-Jan-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Nat Phase62611.000132
    
    ZA
    
    PI920526-5
    
    28-Oct-1992
    
    MICROBIAL OIL MIXTURES AND
USES THEREOF
    
    Granted2997-20-PCN
    
    CN
    
    01816395.5
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-PCZ
    
    CZ
    
    2002-2507
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-PEP
    
    EP
    
    0190211935
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-PHU
    
    HU
    
    P0301967
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-PPL
    
    PL
    
    P362 422
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SR No./ Huntion
    
    
    
    Application or
    
    Appl. Date orNo./ Rothwell No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-20-TH
    
    TH
    
    063197
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-TW
    
    TW
    
    90101741
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Pending2997-20-PUS
    
    US
    
    6,568,351
    
    27-May-2003
    
    Methods for Raising Rabbits
    
    Granted2997-20-PCT
    
    WO
    
    US01/01720
    
    19-Jan-2001
    
    Methods for Raising Rabbits
    
    Nat Phase2997-21-PAU
    
    AU
    
    2001273028
    
    26-Jun-2001
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PCA
    
    CA
    
    2,413,109
    
    27-Nov-2007
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-EPDE
    
    DE
    
    60125176.8-08
    
    13-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PEP
    
    EP
    
    EP1299003
    
    13-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-EPFR
    
    FR
    
    1299003
    
    13-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-EPGB
    
    GB
    
    1299003
    
    13-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PHK
    
    HK
    
    03107219.7
    
    26-Jun-2001
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Published2997-21-EPIT
    
    IT
    
    1299003
    
    13-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PNZ
    
    NZ
    
    523741
    
    26-Jun-2001
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-TH
    
    TH
    
    066509
    
    25-Jun-2001
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Pending2997-21-TW
    
    TW
    
    268761
    
    21-Dec-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PUS
    
    US
    
    7,504,121
    
    17-Mar-2009
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Granted2997-21-PUS-3
    
    US
    
    11/560,809
    
    16-Nov-2006
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Published2997-21-PCT
    
    WO
    
    US01/20471
    
    26-Jun-2001
    
    Improved Methods of
Incorporating
Polyunsaturated Fatty
Acids in Milk
    
    Nat Phase2997-31-PAE
    
    AE
    
    PCT/AE 376/2003
    
    14-May-2002
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Pending2997-31-PAU
    
    AU
    
    2002303744
    
    31-Jul-2008
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Granted2997-31-PCA
    
    CA
    
    2,446,027
    
    14-May-2002
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Pending2997-31-PEP
    
    EP
    
    02731799.9
    
    14-May-2002
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Published2997-31-PJP
    
    JP
    
    2002-588780
    
    14-May-2002
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Pending2997-31-PMX
    
    MX
    
    252263
    
    6-Dec-2007
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Granted2997-31
    
    US
    
    6,716,460
    
    6-Apr-2004
    
    Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Granted
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SR No./ Huntion
    
    
    
    Application or
    
    Appl. Date orNo./ Rothwell No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-31-PCT
    
    WO
    
    US02/15353
    
    14-May-2002
    
    A Method of Improving the
Flavor, Tenderness and
Overall Consumer
Acceptability of Poultry
Meat
    
    Nat Phase2997-38-CON
    
    US
    
    12/111,844
    
    29-Apr-2008
    
    Products Containing Highly
Unsaturated Fatty Acids
For Use by Women During
States of Preconception,
Pregnancy and
Lactation/Post-Partum
    
    Published2997-46-PAU
    
    AU
    
    2003238264
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Pending2997-46-PCA
    
    CA
    
    2489391
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Pending2997-46-PEP
    
    EP
    
    03737159.8
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Published2997-46-EPHK
    
    HK
    
    05109565.1
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Published2997-46-PJP
    
    JP
    
    2004-512524
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Pending2997-46-PJP-DIV
    
    JP
    
    2006-144750
    
    25-May-2006
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Published2997-46-PUS
    
    US
    
    10/518,957
    
    27-Jun-2005
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Pending2997-46-PCT
    
    WO
    
    US03/19108
    
    18-Jun-2003
    
    Stable Emulsions of Oils
in Aqueous Solutions and
Methods for Producing Same
    
    Nat Phase62611.000283
    
    AT
    
    0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000176
    
    AU
    
    693450
    
    5-Nov-1998
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000284
    
    BE
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000177
    
    CA
    
    2164291
    
    30-Oct-2007
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000377
    
    CA
    
    2596241
    
    2-Jun-1994
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Pending62611.000285
    
    CH
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SR No./ Huntion
    
    
    
    Application or
    
    Appl. Date orNo./ Rothwell No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000286
    
    DE
    
    69433713
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000287
    
    DK
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000301
    
    EP
    
    04075413.7
    
    2-Jun-1994
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Published62611.000178
    
    EP
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    EPGrant62611.000288
    
    ES
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000289
    
    FR
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000290
    
    GB
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000291
    
    GR
    
    20040401791
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000292
    
    IE
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000293
    
    IT
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000179
    
    JP
    
    501997/95
    
    2-Jun-1994
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Published62611.000381
    
    JP
    
    2007-327930
    
    19-Dec-2007
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Published62611.000294
    
    LU
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000295
    
    MC
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SR No./ Huntion
    
    
    
    Application or
    
    Appl. Date orNo./ Rothwell No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000180
    
    MX
    
    263227
    
    17-Dec-2008
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611-000393
    
    MX
    
    MX/A/2008/013240
    
    31-Oct-2008
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Pending62611.000296
    
    NL
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000297
    
    PT
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000298
    
    SE
    
    EP0707487
    
    14-Apr-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Granted62611.000300
    
    US
    
    10/855,488
    
    28-May-2004
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Published62611.000186
    
    US
    
    08/479,809
    
    7-Jun-1995
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Pending62611.000181
    
    WO
    
    PCT/US94/06317
    
    2-Jun-1994
    
    METHODS AND PHARMACEUTICAL
COMPOSITIONS USEFUL FOR
TREATING NEUROLOGICAL
DISORDERS
    
    Nat Phase62611.000183
    
    AU
    
    768369
    
    25-Mar-2004
    
    METHODS FOR CONTROLLING
HIGHLY UNSATURATED FATTY
ACID CONTENT IN VARIOUS
TISSUES
    
    Granted62611.000184
    
    EP
    
    96921263.8
    
    3-Jun-1996
    
    METHODS FOR CONTROLLING
HIGHLY UNSATURATED FATTY
ACID CONTENT IN VARIOUS
TISSUES
    
    Published62611.000390
    
    EP
    
    07075522.8
    
    3-Jun-1996
    
    METHODS FOR CONTROLLING
HIGHLY UNSATURATED FATTY
ACID CONTENT IN VARIOUS
TISSUES
    
    Pending62611.000185
    
    IL
    
    122405
    
    11-Jul-2003
    
    METHODS FOR CONTROLLING
HIGHLY UNSATURATED FATTY
ACID CONTENT IN VARIOUS
TISSUES
    
    Granted62611.000187
    
    WO
    
    PCT/US96/08649
    
    3-Jun-1996
    
    METHODS FOR CONTROLLING
HIGHLY UNSATURATED FATTY
ACID CONTENT IN VARIOUS
TISSUES
    
    Nat Phase
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.69
MARTEK FINISHED OIL SPECIFICATIONS
 ARASCO®Product Specifications
    
    (MARTEK LIFE ENRICHED LOGO)
 General CharacteristicsDescription:
    
    Vegetable oil from fungi, containing approximately 40% arachidonic acid (ARA)Appearance:
    
    Free flowing yellow liquid oil (triglyceride)Aroma:
    
    CharacteristicAntioxidants:
    
    *
 Chemical Characteristics
    
    
    
    Specification*
    
    
    
    *Free Fatty Acid
    
    
    
    max 0.4 %*
    
    
    
    *Elemental Composition
    
    
    
    Specification*
    
    **
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    **
    
    *Fatty Acid Profile, Area %
    
    
    
    Specification*
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    **
    
    **
    
    
    
    **
    
    
    
    **
    
    
    
    *
 Product Storage and Stability
   Ingredients
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.77
GUARANTY AGREEMENT
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



CORPORATE GUARANTY
 THIS CORPORATE GUARANTY
 WHEREAS,
 WHEREAS
 WHEREAS
 WHEREAS
 NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
 1. Arbitral Award Guaranty.
     *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



2. Bankruptcy.
   3. Claims.
  4. Term Date.
  5. Licenses.
  6. Limitations.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



7. Article *.
  8. Notices.
  
  
 9. Governing Law.
  10. Assignment.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



11. Acknowledgement.
  12. No Waiver.
  13. Confession of Judgment.
   *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



IN WITNESS WHEREOF
 *
 By:
    
    *
    
    By:
    
    *Name: *
    
    
    
    Name: *Title: Member of the Managing Board of Directors
    
    
    
    Title: Director Corporate Legal Affairs
 MARTEK BIOSCIENCES CORPORATIONBy:
    /s/ Steve DubinName:
    Steve DubinTitle:
    President *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.104
MARTEK COSTS
 Included Costs:
    Excluded Costs:
  
    
    All costs related to the importing and re-exporting of ARA products sent to DSM that
do not meet applicable Specifications, including but not limited to related freight,
tariffs and warehousing costs.
 
    
    Costs related to reworking material that originally did not meet applicable
Specifications pursuant to Section 4.7 of the Agreement.
 
    
    Legal costs associated with negotiating and drafting the Alliance Agreement as amended
and the Restated Agreement.
 
    
    R&D Contribution pursuant to Section 7.1(d).
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.108
MARTEK PATENTS
 Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-4-1
    
    US
    
    5,882,703
    
    16-Mar-1999
    
    Product Containing Mortierella Sect.
Schmuckeri Lipids
    
    Granted2997-4
    
    US
    
    5,583,019
    
    10-Dec-1996
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-1-1
    
    US
    
    6,245,365
    
    12-Jun-2001
    
    Product Containing Mortierella Sect.
Schmuckeri Lipids
    
    Granted2997-4-1-1-1
    
    US
    
    6,319,698
    
    20-Nov-2001
    
    Method for Producing Arachidonic Acid
    
    Granted2997-4-1-1-2
    
    US
    
    6,749,849
    
    15-Jun-2004
    
    Method for Producing Arachidonic Acid
(as amended)
    
    Granted2997-4-1-1-2-1
    
    US
    
    7,195,791
    
    27-Mar-2007
    
    Method for Production of Archidontic Acid
    
    Granted2997-4-1-1-2-1-1
    
    US
    
    11/531,439
    
    13-Sep-2006
    
    Method for Production of Arachidonic Acid
    
    Published2997-4-1-1-2-1-1-C1
    
    US
    
    11/782,466
    
    24-Jul-2007
    
    Method for Production of Arachidonic Acid
    
    Published2997-4-1-1-2-1-1-C2
    
    US
    
    11/782,571
    
    24-Jul-2007
    
    Method for Production of Arachidonic Acid
    
    Published2997-4-1-2
    
    US
    
    6,541,049
    
    1-Apr-2003
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-AU
    
    AU
    
    711967
    
    10-Feb-2000
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-CA
    
    CA
    
    2163278
    
    20-Nov-1995
    
    Method for Production of Arachidonic Acid
    
    Pending2997-4-EP
    
    EP
    
    EP0726321
    
    12-Jun-2002
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-EPDE
    
    DE
    
    69621663.9-08
    
    12-Jun-2002
    
    Arachidonic Acid
    
    Granted2997-4-EP-DIV-1
    
    EP
    
    6008737.6
    
    16-Jan-1996
    
    Method for Production of Arachidonic Acid
    
    Published2997-4-EP-DIV-HK
    
    HK
    
    2106865.7
    
    16-Jan-1996
    
    Method for Production of Arachidonic Acid
    
    Pending2997-4-EPFR
    
    FR
    
    EP0726321
    
    12-Jun-2002
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-EPGB
    
    GB
    
    EP0726321
    
    12-Jun-2002
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-EPIT
    
    IT
    
    EP0726321
    
    12-Jun-2002
    
    Method for Production of Arachidonic Acid
    
    Granted2997-4-JP
    
    JP
    
    7-314330
    
    1-Dec-1995
    
    Method for Production of Arachidonic Acid
    
    Pending2997-4-JP-DIV-2
    
    JP
    
    2007-336075
    
    27-Dec-2007
    
    Method for Production of Arachidonic Acid
    
    Published2997-19-PAU-1-1
    
    AU
    
    2008229885
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PAU-1
    
    AU
    
    2005202980
    
    30-Jun-2008
    
    Solventless Extraction Process
    
    Granted2997-19-PAU
    
    AU
    
    780619
    
    7-Apr-2005
    
    Solventless Extraction Process
    
    Granted2997-19-PBR
    
    BR
    
    PI0107699-0
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PCA
    
    CA
    
    2,397,665
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PCN
    
    CN
    
    zk01806424.8
    
    11-Feb-2009
    
    Solventless Extraction Process
    
    Granted2997-19-PCN-DIV
    
    CN
    
    200810184934.X
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PCZ
    
    CZ
    
    2002-2506
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PEP
    
    EP
    
    1942672.5
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PHK
    
    HK
    
    03102740.6
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Published2997-19-PHU
    
    HU
    
    P0300556
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PID
    
    ID
    
    WO0200201683
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PIL
    
    IL
    
    150772
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-19-PIN-1
    
    IN
    
    6878/DELNP/2006
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PIN
    
    IN
    
    2002/00711/DEL
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PJP
    
    JP
    
    4020642
    
    5-Oct-2007
    
    Solventless Extraction Process
    
    Granted2997-19-PJP-1
    
    JP
    
    2005-137044
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Published2997-19-PKR
    
    KR
    
    2002-7009287
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PMX-1
    
    MX
    
    PA/a/2005/009334
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PMX
    
    MX
    
    232230
    
    18-Nov-2005
    
    Solventless Extraction Process
    
    Granted2997-19-PNO
    
    NO
    
    20023449
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PNZ
    
    NZ
    
    520287
    
    10-May-2004
    
    Solventless Extraction Process
    
    Granted2997-19-PPL
    
    PL
    
    P356587
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PPL-1
    
    PL
    
    P387119
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-PRU
    
    RU
    
    2336307
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Granted2997-19-PSG
    
    SG
    
    90582
    
    28-Feb-2006
    
    Solventless Extraction Process
    
    Granted2997-19-TH
    
    TH
    
    063198
    
    22-Jan-2001
    
    Solventless Extraction Process
    
    Pending2997-19-TW-1
    
    TW
    
    94128361
    
    8-Mar-2001
    
    Solventless Extraction Process
    
    Pending2997-19-TW
    
    TW
    
    I 293648
    
    21-Feb-2008
    
    Solventless Extraction Process
    
    Granted2997-19-1-C3
    
    US
    
    11/782,449
    
    24-Jul-2007
    
    Solventless Extraction Process
    
    Published2997-19-1-C2
    
    US
    
    11/782,434
    
    24-Jul-2007
    
    Solventless Extraction Process
    
    Published2997-19-1-C1
    
    US
    
    11/782,416
    
    24-Jul-2007
    
    Solventless Extraction Process
    
    Published2997-19
    
    US
    
    6,750,048
    
    15-Jun-2004
    
    Solventless Extraction Process
    
    Granted2997-19-1
    
    US
    
    7,351,558
    
    1-Apr-2008
    
    Solventless Extraction Process
    
    Granted2997-19-PCT
    
    WO
    
    US01/01806
    
    19-Jan-2001
    
    Solventless Extraction Process
    
    Nat Phase2997-19-PZA
    
    ZA
    
    2002/5790
    
    23-Sep-2003
    
    Solventless Extraction Process
    
    Granted2997-42-PAU-DIV
    
    AU
    
    2009200718
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
from Oil Seed and Microbia Sources
    
    Pending2997-42-PAU
    
    AU
    
    2002366642
    
    26-Mar-2009
    
    Extraction and Winterization of Lipids
From Oil Seed and Microbial Sources
    
    Granted2997-42-PCA
    
    CA
    
    2469647
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
From Oil Seed and Microbial Sources
    
    Pending2997-42-PCN
    
    CN
    
    ZL02828043.1
    
    2-Aug-2006
    
    Extraction and Winterization of Lipids
from Oilseed and Microbial Sources
    
    Granted2997-42-PEP
    
    EP
    
    02791414.2
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
from Oilseed and Microbial Sources
    
    Published2997-42-PJP
    
    JP
    
    2003-550880
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
from Oilseed and Microbial Sources
    
    Published2997-42-PNO
    
    NO
    
    20042929
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
From Oilseed and Microbial Sources
    
    Pending2997-42-PUS
    
    US
    
    7,419,596
    
    2-Sep-2008
    
    Extraction and Winterization of Lipids
From Oilseed and Microbial Sources
    
    Granted2997-42-PUS-1
    
    US
    
    12/184,974
    
    1-Aug-2008
    
    Extraction and Winterization of Lipids
From Oilseed and Microbial Sources
    
    Published2997-42-PCT
    
    WO
    
    US02/39930
    
    12-Dec-2002
    
    Extraction and Winterization of Lipids
from Oilseed and Microbial Sources
    
    Nat Phase2997-45-PAU
    
    AU
    
    2003237182
    
    8-Jan-2009
    
    High-Quality Lipids and Methods for
Producing by Enzymatic Liberation form
Biomass
    
    Granted2997-45-PAU-1
    
    AU
    
    2008252072
    
    3-May-2003
    
    High-Quality Lippids and Methods for
Producing by Enzymatic Liberation from
Biomass
    
    Pending
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-45-PCA
    
    CA
    
    2484334
    
    3-May-2003
    
    High-Quality Lipids and Methods for
Producing by Enzymatic Liberation From
Biomass
    
    Pending2997-45-PEP
    
    EP
    
    03736552.5
    
    3-May-2003
    
    HIGH-QUALITY LIPIDS AND METHODS FOR
PRODUCING BY ENZYMATIC LIBERATION FROM
BIOMASS
    
    Published2997-45-1
    
    US
    
    10/971,723
    
    22-Oct-2004
    
    Methods for Producing Lipids by
Liberation from Biomass
    
    Published2997-45-PUS
    
    US
    
    10/513,576
    
    11-Oct-2005
    
    High-Quality Lipids and Methods for
Producing by Enzymatic Liberation From
Biomass
    
    Published2997-45-PCT
    
    WO
    
    PCT/US03/14177
    
    3-May-2003
    
    High-Quality Lipids and Methods for
Production by Enzymatic Liberation from
Biomass
    
    Nat Phase2997-46-PAU
    
    AU
    
    2003238264
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Pending2997-46-PCA
    
    CA
    
    2489391
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Pending2997-46-PEP
    
    EP
    
    03737159.8
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Published2997-46-EPHK
    
    HK
    
    05109565.1
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Published2997-46-PJP
    
    JP
    
    2004-512524
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Pending2997-46-PJP-DIV
    
    JP
    
    2006-144750
    
    25-May-2006
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Published2997-46-PUS
    
    US
    
    10/518,957
    
    27-Jun-2005
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Pending2997-46-PCT
    
    WO
    
    US03/19108
    
    18-Jun-2003
    
    Stable Emulsions of Oils in Aqueous
Solutions and Methods for Producing Same
    
    Nat Phase62611.000324-AT
    
    AT
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000009
    
    AU
    
    661674
    
    21-Nov-1995
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-BE
    
    BE
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000012
    
    BR
    
    PI9205519.2
    
    22-Jan-1992
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Appealed62611.000013
    
    CA
    
    2101273
    
    2-Apr-2002
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-CH
    
    CH
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-DE
    
    DE
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-DK
    
    DK
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000352
    
    EP
    
    06077261.3
    
    22-Jan-1992
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000324
    
    EP
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    EPGrant62611.000324-ES
    
    ES
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-FR
    
    FR
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-GB
    
    GB
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-GR
    
    GR
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000378
    
    HK
    
    07113851.4
    
    19-Dec-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000021
    
    ID
    
    ID0000393
    
    22-Dec-1995
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000022
    
    IL
    
    100732
    
    1-Oct-1995
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-IT
    
    IT
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-LU
    
    LU
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-MC
    
    MC
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000124
    
    MX
    
    183638
    
    6-Jan-1997
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000027
    
    MX
    
    202940
    
    6-Jul-2001
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-NL
    
    NL
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000030
    
    NZ
    
    241358
    
    8-Feb-1995
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000032
    
    PH
    
    1992-43811
    
    22-Aug-2002
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000033
    
    RU
    
    2120998
    
    22-Jan-1992
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000324-SE
    
    SE
    
    EP1642983
    
    11-Apr-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000057
    
    US
    
    5658767
    
    19-Aug-1997
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000031
    
    WO
    
    PCT/US92/00517
    
    22-Jan-1992
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Nat Phase62611.000034
    
    ZA
    
    92/0454
    
    28-Oct-1992
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000273
    
    AT
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000043
    
    AU
    
    713567
    
    16-Mar-2000
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000274
    
    BE
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000359
    
    BR
    
    PI9612999-9
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending62611.000044
    
    BR
    
    PI9607179-6
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000045
    
    CA
    
    2209513
    
    28-May-2002
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000272
    
    CH
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000321
    
    CN
    
    
    200510071295.2
    
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000046
    
    CN
    
    96192002.5
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000397
    
    CN
    
    
    200910006766.X
    
    
    3-Jan-1996
    
    Arachidonic Acid and Methods for the
Production and Use Thereof
    
    Pending62611.000271
    
    DE
    
    69627816.2
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000275
    
    DK
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000058
    
    EA
    
    001036
    
    28-Aug-2000
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000048
    
    EP
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    EPGrant62611.000260
    
    EP
    
    03076254.6
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000276
    
    ES
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000347
    
    FI
    
    20060617
    
    26-Jun-2006
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000049
    
    FI
    
    117442
    
    13-Oct-2006
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000270
    
    FR
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000269
    
    GB
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000268
    
    GR
    
    20030402977
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000346
    
    HK
    
    06105700.4
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000299
    
    HK
    
    04101355.3
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000267
    
    IE
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000266
    
    IT
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000326
    
    JP
    
    2009-80997
    
    30-Mar-2009
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending62611.000401
    
    JP
    
    2009-80997
    
    30-Mar-2009
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending62611.000050
    
    JP
    
    4014219
    
    21-Sep-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000325
    
    JP
    
    2005-368593
    
    21-Dec-2005
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000326
    
    JP
    
    2007-158505
    
    15-Jun-2007
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Published62611.000348
    
    KR
    
    10-2006-7015060
    
    26-Jul-2006
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending62611.000357
    
    KR
    
    10-2008-7015041
    
    20-Jun-2008
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Pending62611.000265
    
    LU
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000263
    
    MC
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000051
    
    MX
    
    234429
    
    13-Feb-2006
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000264
    
    NL
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status62611.000052
    
    NO
    
    320117
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000054
    
    PL
    
    187694
    
    14-Jan-2004
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000261
    
    PT
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000262
    
    SE
    
    EP0800584
    
    2-May-2003
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000055
    
    SG
    
    42669
    
    30-Mar-1999
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Granted62611.000053
    
    WO
    
    PCT/US96/00182
    
    3-Jan-1996
    
    ARACHIDONIC ACID AND METHODS FOR THE
PRODUCTION AND USE THEREOF
    
    Nat Phase62611.000105
    
    US
    
    6166231
    
    26-Dec-2000
    
    TWO PHASE EXTRACTION OF OIL FROM BIOMASS
    
    Granted2997-33-PAE
    
    AE
    
    PCT/AE 378/2003
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Pending2997-33-PAU-DIV
    
    AU
    
    2009200194
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Moeified
Plant Seeds and Marine Organisms
    
    Pending2997-33-PAU
    
    AU
    
    2002309856
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Published2997-33-PCA
    
    CA
    
    2,451,116
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Pending2997-33-PEP
    
    EP
    
    02736881.0
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Published2997-33-PJP
    
    JP
    
    2002-589426
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Published
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



Application or
    
    Appl. Date orSR/ No./ Hunton No.
    
    Country
    
    Patent Number
    
    Date Issued
    
    Title of Patent
    
    Status2997-33-PJP-DIV
    
    JP
    
    2007-289167
    
    21-Oct-2004
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Published2997-33-PMX
    
    MX
    
    PA/a/2003/010399
    
    14-May-2002
    
    Production and Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
From Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Pending2997-33-PUS
    
    US
    
    10/457,066
    
    21-Oct-2004
    
    Production and Use of a Polar Lipid-Rich
Fraction
    
    Pending2997-33-PCT
    
    WO
    
    US02/15454
    
    14-May-2002
    
    Production of Use of a Polar Lipid-Rich
Fraction Containing Omega-3 and/or
Omega-6 Highly Unsaturated Fatty Acids
from Microbes, Genetically Modified
Plant Seeds and Marine Organisms
    
    Nat Phase
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance
on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been
submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.109
MARTEK KNOW-HOW
 Main fields of expertise:
 Strains and strain improvement methodologies:
 
    
    Strains identified with significantly higher productivity and ARA potency than the *
 
    
    *
 
    
    *
 Fermentation:
 
    
    *
 
    
    *
 Downstream Processing:
 
    
    *
 
    
    *
 
    
    *
 
    
    *
 
    
    *
 
    
    *
 Product Formulation:
 
    
    *
 
    
    *
 Product Characterization:
 
    
    *
 Transgenic Oilseeds:
 
    
    *
 Feed Applications:
 
    
    *
 
    
    *
 
    
    *
 
    
    *
 Ingredient Forms:
 
    
    *
 
    
    *
 Product Safety and Toxicology:
 
    
    *
 
    
    *
 Product Efficacy & Health Benefits:
 
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 2.118
* CUSTOMERS
 1.
    
    *
 2.
    
    *
 3.
    
    *
 4.
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 4.2(a)
DSM BIOMASS CERTIFICATE OF ANALYSIS
 (DSM LOGO)
    
    Certificate of Analysis
    
    ARA-CoA-004MARA Biomass
    
    Revision 113 July 2009
 Product no: 2984
 Parameters
    
    Requirements
    
    ResultDescription
    
    GranulateSmell
    
    CharacteristicColor
    
    Brown*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
  
    
    Below -2°C +/- 3°C, preferably lower temperatures
    
    Protected from light
    
    Dry conditions
  
    
    Big Bags (polypropylene with polyethylene liner), anti static
    
    Labeled with product number, batch number, production number, production date and storage conditions on both inner and outer bag
   Date:
    
    QA-Manager:
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 4.2(b)
MARTEK FINISHED OIL CERTIFICATE OF ANALYSIS
 (MARTEK LOGO)
    
    Certificate of AnalysisARASCO®Arachidonic AcidLot No.
    
    
    
    *Country of Origin
    
    
    
    United StatesDate of Manufacture
    
    
    
    *Expiration Date (frozen, -20oC)
    
    
    
    *
 General CharacteristicsDescription:
    
    Vegetable oil from fungi, which contains approximately 40% Arachidonic Acid (ARA)Appearance:
    
    Clear, free flowing yellow liquid oil (triglyceride) at 40oCAroma
    
    CharacteristicAntioxidants
    
    *
 Chemical Characteristics
    
    Units
    
    Specification
    
    ResultArachidonic Acid
    
    Area %
    
    *
    
    *Arachidonic Acid
    
    mg/g
    
     *
    
    **
    
    %
    
    *
    
    *Free Fatty Acid
    
    %
    
    max 0.4
    
    **
    
    meq/kg
    
    *
    
    **
    
    %
    
    *
    
    **
    
    %
    
    *
    
    **
    
    %
    
    *
    
    **
    
    %
    
    *
    
    *
 Elemental Composition
    
    Units
    
    Specification
    
    Result*
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    **
    
    ppm
    
    *
    
    *
 Fatty Acid Profile
    
    Units
    
    
    Specification
    
    
    Result*
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    **
    
    Area %
    
    
    *
    
    
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



Martek Biosciences Corporation certifies this product is vegetable oil from fungi, which
contains approximately 40% Arachidonic Acid (ARA), and meets the product specifications as
outlined above. ARASCO®is Kosher and Halal Certified and is BSE/TSE free.
    
    Released By:
    
    Jennifer ZaffaranoRelease Specialist I
 *
    
    Martek will endorse the results of this Certificate of Analysis for a period of up to three years from the date of manufacture if the material is stored frozen (~-20°C) in the original, unopened containers.
Beyond three years, we recommend the quality of the material be confirmed prior to use, by retesting the Certificate of Analysis parameters. Martek Biosciences Corporation
    
    Martek Biosciences Boulder Corporation
    
    Martek Biosciences Kingstree Corporation
    
    Martek Biosciences Corporation6480 Dobbin Road
    
    4909 Nautilus Court North
    
    1416 N. Williamsburg County Highway
    
    555 Rolling Hills LaneColumbia, MD 21045
    
    Boulder, CO 80301
    
    Kingstree, SC 29556
    
    Winchester, KY 40391(800) 662-6339
    
    (303) 381-8100
    
    (843) 381-8485
    
    (859) 744-0920(410) 740-0081
    
    Research and Development
    
    Manufacturing
    
    ManufacturingCustomer Service
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 4.6(a)
MANUFACTURING CHANGES
 A. Documentation:
 B. Major vs. minor changes:
 
    
    Minor changes(Any change that has an impact to yield or process efficiency)
 
    
    Fermentation *.
    
    Pasteurization, Filtration, Extrusion and Drying *.
    
    Extraction and RBD *.
 
    
    Major changes(Any change that has or may have a detectable and significant
effect on final product properties as specified in the product specification forms)
 
    
    Fermentation *.
    
    Pasteurization, Filtration, Extrusion and Drying *.
    
    Extraction and RBD *.
  C. Customer notification requirements:
 
    
    Both parties will provide pre-notification of any change to production controls,
processes and test methods to allow the other party to determine if a change is major or
minor prior to implementation.
 
    
    All major process and test method changes require approval of the other party prior to
implementation.
 
    
    Martek is responsible to determine if and when process or test method changes require
customer notification within the Martek ARA Fields of Use.
 
    
    Martek is responsible to determine if and when a process or test methods change requires
regulatory review within the Martek ARA Fields of Use.
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 4.6(b)
QUALIFICATION REQUIREMENTS
 Physical Description
    
    
    
    MethodDescription:
    
    Vegetable oil from m. alpina fungiAppearance:
    
    Clear, free-flowing liquid at 40° C
    
    VisualColor:
    
    Light-medium yellow
    
    VisualOdor:
    
    Characteristic (1)
    
    Sensory panel evaluation
 Fatty Acid Composition
    
    
    
    
    
    Sensory Limits (1)*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
    
    **
    
    *
    
    **
    
    *
    
    *
    
    Stability*
    
    *
    
    *
    
    *Others
    
    
    
    *
 Chemical Analyses
    
    Units
    
    Minimum
    
    Maximum
    
    Method*
    
    mg/g
    
    *
    
    *
    
    **
    
    %
    
    *
    
    *
    
    **
    
    meq/kg
    
    *
    
    *
    
    **
    
    
    
    *
    
    *
    
    **
    
    
    
    *
    
    *
    
    **
    
    %
    
    *
    
    *
    
    **
    
    %
    
    *
    
    *
    
    **
    
    %
    
    *
    
    *
    
    **
    
    %
    
    *
    
    *
    
    *Elemental Analyses*
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    **
    
    ppm
    
    *
    
    *
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 6.1-A
BELVIDERE USAGES
 Variable Cost Component
    
    UOM
    
    2009
    
    2010
    
    2011
    
    2012
    
    2013
    
    2014Dextrose
    
    Kg/Unit
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *Yeast Extract
    
    Kg/Unit
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *Electricity
    
    kWh/Unit
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *Natural Gas
    
    Dthm/Unit
    
    *
    
    *
    
    *
    
    *
    
    *
    
    *
  *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 6.1-B
2009 DSM VARIABLE COSTS PER UNIT OF ARA
 Capua
    
    Units
    
    
    Rate
    
    
    Usage/Unit
    
    
    Cost/UnitDextrose
    
    /Kg
    
    
    *
    
    
    
    *
    
    
    
    *Yeast Extract
    
    /Kg
    
    
    *
    
    
    
    *
    
    
    
    *Electricity
    
    /kWh
    
    
    *
    
    
    
    *
    
    
    
    *Natural Gas
    
    /mc
    
    
    *
    
    
    
    *
    
    
    
    *Other
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    **@ $*/
    
    
    *
 Belvidere
    
    Units
    
    
    Rate
    
    
    Usage/Unit
    
    
    Cost/UnitDextrose
    
    $/Kg
    
    
    *
    
    
    
    *
    
    
    
    *Yeast Extract
    
    $/Kg
    
    
    *
    
    
    
    *
    
    
    
    *Electricity
    
    $/kWh
    
    
    *
    
    
    
    *
    
    
    
    *Natural Gas
    
    $/Dthm
    
    
    *
    
    
    
    *
    
    
    
    *Other
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    **
 2009 Volume (MT)
    
    
    Total Cost (000s)Capua
    
    
    *
    
    
    
    *Belvidere
    
    
    *
    
    
    
    *Total
    
    
    *
    
    
    
    *Weighted average Variable Cost per Unit of ARA
    
    
    
    
    
    
    *
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities
Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 6.2-A
2009 QUARTERLY RECONCILIATION FORMAT
 2009 Quarterly Reconciliation
 Total (Credit)/Debit
    
    
    *
    
    
    
    *
 2009 Budgeted Price per Kg of 40% ARA Crude Oil
 DSM Fixed Costs
    
    
    
    
    
    $
    *DSM Variable Costs
    
    
    
    
    
    $
    *DSM Mark Up
    
    
    
    
    
    $
    *Budgeted Price (Kg)
    
    
    *
    
    
    $
    **
    
    
    
    *-
    
    
    
    -Conversion Factor (Biomass:Crude Oil)
    
    
    *
    
    
    
    *Budgeted Biomass Price (Kg)
    
    
    *
    
    
    $
    *
 Volume and Currency Reconciliation
 Total 40% Crude Oil Extracted (Kg)
    
    
    ** Volume Split
    
    
    *
    
    
    
    *Total Amounts Due
    
    
    *
    
    
    $
    *Invoice Amounts Paid
    
    
    *
    
    
    $
    *$
    *
    
    
    (Credit)/Debit
    *
    
    
    (Credit)/Debit
 Rate Reconciliation
 Budgeted*
    
    Budget Rate
    
    
    Actual Rate
    
    
    Usage
    
    
    
    
    
    Delta*
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    
    
    
    
    **
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    
    
    
    
    **
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    
    
    
    
    **
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    +
    
    
    
    *
    *
    
    
    Total DeltaX
    
    
    
    *
    
    
    Crude Oil (Kg)
    *
    
    
    (Credit)/Debit**
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    
    
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    
    
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    
    
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    
    
    
    
    $
    *$
    *
    
    
    Total Delta*
    
    
    Crude Oil (Kg)$
    *
    
    
    (Credit)/Debit
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in
reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions
have been submitted separately to the Securities and Exchange Commission




---



##### 



RBD Yield Reconciliation
 Total 40% Crude Oil In (Kg)
    
    
    *Total 40% Finished Oil Out (Kg)
    
    
    *
    
    
    
    *
    
    
    YieldTotal 40% Finished Oil Expected (Kg)
    
    
    *
    
    
    
    *
    
    
    Yield-40% Finished Oil Difference
    
    
    *40% Crude Oil Difference
    
    
    *50% of Variable Costs
    
    $
    *100% of DSM Mark Up
    
    $
    *50% Variable Cost + 100% DSM Mark Up
    
    $
    *$
    *
    
    
    (Credit)/Debit
 Martek Profit Sharing Fee (Q4 only)
    
    $
    *
    
    
    DebitDSM ARA Field of Use & Adult ARA Applications Royalty (Q4 only)
    
    $
    *
    
    
    (Credit)
 Adjusted Annual Fixed Costs Reconciliation (Q4 only)
 Total 40% Crude Oil Delivered to Martek (Kg)
    
    
    *
    
    
    (excluding Carryover Units)Total 40% Crude Oil Produced by DSM (Kg)
    
    
    *
    
    
    (excluding Carryover Units)*Agreed Annual Fixed Costs
    
    $
    *Adjusted Annual Fixed Costs
    
    $
    *Aggregate Agreed Annual Fixed Costs per Unit of ARA paid
    
    $
    *$
    *
    
    
    (Credit)/Debit
 Note:
    
    the above reconciliation format example illustrates common calculations, but does not include all possible reconciliation lines.*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 6.2-B
2010-2014 QUARTERLY RECONCILIATION FORMAT
 2010 Quarterly Reconciliation
 Total (Credit)/Debit
    
    
    *
    
    
    
    *
 2010 Budgeted Price per Kg of 40% ARA Crude Oil
 DSM Fixed Costs
    
    
    
    
    
    $
    *DSM Variable Costs
    
    
    
    
    
    $
    *DSM Mark Up
    
    
    
    
    
    $
    *Budgeted Price (Kg)
    
    
    *
    
    
    $
    **-
    
    
    
    -Conversion Factor (Biomass:Crude Oil)
    
    
    
    
    
    
    *Budgeted Biomass Price (Kg)
    
    
    
    
    
    $
    *
 Volume and Currency Reconciliation
 Total 40% Crude Oil Extracted (Kg)
    
    
    *25%-75% Volume Split
    
    
    *
    
    
    
    *Total Amounts Due
    
    
    *
    
    
    $
    *Invoice Amounts Paid
    
    
    *
    
    
    $
    *$
    *
    
    
    (Credit)/Debit
    *
    
    
    (Credit)/Debit
 Rate Reconciliation
 Budgeted*
    
    Budget Rate
    
    
    Actual Rate
    
    
    Usage
    
    
    Delta*
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    $
    **
    
    $
    *
    
    
    $
    *
    
    
    
    *
    
    
    $
    *$
    *
    
    
    Total Delta*
    
    
    Crude Oil (Kg)$
    *
    
    
    (Credit)/Debit
 RBD Yield Reconciliation
 Total 40% Crude Oil In (Kg)
    
    
    *Total 40% Finished Oil Out (Kg)
    
    
    *
    
    
    
    *
    
    
    YieldTotal 40% Finished Oil Expected (Kg)
    
    
    *
    
    
    
    *
    
    
    Yield-40% Finished Oil Difference
    
    
    *40% Crude Oil Difference
    
    
    *50% of Variable Costs
    
    $
    *100% of DSM Mark Up
    
    $
    *50% Variable Cost + 100% DSM Mark Up
    
    $
    *$
    *
    
    
    (Credit)/Debit
 *
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



Martek Profit Sharing Fee (Q4 only)
    
    $
    *
    
    
    DebitDSM ARA Field of Use & Adult ARA Applications Royalty (Q4 only)
    
    $
    *
    
    
    (Credit)
 Adjusted Annual Fixed Costs Reconciliation (Q4 only)
 Total 40% Crude Oil Delivered to Martek (Kg)
    
    
    *
    
    
    (excluding Carryover Units)Total 40% Crude Oil Produced by DSM (Kg)
    
    
    *
    
    
    (excluding Carryover Units)*Agreed Annual Fixed Costs
    
    $
    *Adjusted Annual Fixed Costs
    
    $
    *Aggregate Agreed Annual Fixed Costs per Unit of ARA paid
    
    $
    *$
    *
    
    
    (Credit)/Debit
 Note:
    
    the above reconciliation format example illustrates common calculations, but does not include all possible reconciliation lines.*
    
    The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on
Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted
separately to the Securities and Exchange Commission




---



##### 



SCHEDULE 6.3(a)
DSM FIXED COSTS PAYMENT CALCULATION IN THE EVENT OF DSM SHORTFALLS




---



##### 



Example 1Units of ARA forcasted for purchase (prior Nov)
    
    
    *Agreed Annual Fixed Costs
    
    $
    *Agreed Annual Fixed Costs per Unit of ARA
    
    $
    *Units of ARA delivered to Martek
    
    
    *Total Units of ARA produced by DSM
    
    
    *Ratio of Units of ARA delived to produced
    
    
    *(A) Adjusted Annual Fixed Costs
    
    $
    *(B) Aggregate sum of DSM Fixed Costs paid
    
    $
    *Difference to be paid to DSM
    
    $
    *
 Example 2
    
    Year 1-Q1
    
    
    Year 1-Q2
    
    
    Year 1-Q3
    
    
    Year 1-Q4
    
    
    Year 2-Q1
    
    
    Year 2-Q2
    
    
    Year 2-Q3
    
    
    Year 2-Q4Units of ARA forcasted for purchase (prior Nov)
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Agreed Annual Fixed Costs
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Agreed Annual Fixed Costs per Unit of ARA
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Units of ARA requested in Martek Firm Order
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Units of ARA delivered to Martek
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *DSM Shortfall
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Cumulative four (4) Rolling DSM Shortfall
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Units of ARA delivered to Martek
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Total Units of ARA produced by DSM
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Ratio of Units of ARA delived to produced
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Adjusted Annual Fixed Costs
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Units of ARA requesed in Martek Firm Orders
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Shortfall Fixed Costs per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *(A) Adjusted Annual Fixed Costs
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *(B) Aggregate sum of DSM Fixed Costs paid
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Difference to be paid to DSM
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    (Credit) to Martek
    
    $
    *Shortfall Fixed Costs
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Aggregate sum of DSM Fixed Costs paid
    
    
    
    
    
    
    
    
    
    
    *
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    -
    
    
    $
    *6.3(a)(ii) (Credit)/Debit
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Units of ARA produced and sold by Martek > 40,000 Units
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    *Shortfall Fixed Costs per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    x
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    x
    
    
    $
    *6.3(a)(i)(X)Debit
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *DSM Mark Up per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Adjusted DSM Variable Cost per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *Shortfall Fixed Costs per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    +
    
    
    $
    *Sum
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    =
    
    
    $
    *Third party price per Unit of ARA
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    -
    
    
    $
    *Difference
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    =
    
    
    $
    *Units of ARA produced by a third party and sold by Martek > 40,000 Units
    
    
    
    
    
    
    
    
    
    
    
    
    *
    
    
    
    
    
    
    
    
    
    
    
    x
    
    
    
    *6.3(a)(i)(Y) Debit
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    =
    
    
    $
    *Total (Credit)/Debit
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    $
    *




---



##### 



SCHEDULE 9.4(d)-1
ANNUAL DEPRECIATION OF UNDEPRECIATED * COSTS
 2009
    
    
    2010
    
    
    2011
    
    
    2012
    
    
    2013
    
    
    2014
    
    
    2015
    
    
    2016
    
    
    2017
    
    
    2018Total Beginning Book
Value of Undepreciated *
Costs
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Fermentors and EquipmentPhase 1 Project
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Phase 2 Project
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Fire Upgrades
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *BuildingPhase 1 Project
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Phase 2 Project
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Additional ARA InvestmentsPrior to 2009
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Total Ending Book Value
of Undepreciated * Costs
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *




---



##### 



SCHEDULE 9.4(d)-2
ANNUAL DEPRECIATION OF UNDEPRECIATED PRE-2004 COSTS
 2009
    
    
    2010
    
    
    2011
    
    
    2012
    
    
    2013
    
    
    2014
    
    
    2015Total Beginning Book
Value of Undepreciated
Pre-2004 Costs
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Fermentors and EquipmentPhase 1 Existing
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Phase 2 Existing
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *BuildingPhase 1 Existing
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Phase 2 Existing
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Shared AssetsPilot Plant
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Utilities
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *Total Ending Book Value
of Undepreciated
Pre-2004 Costs
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *
    
    
    
    *